Orion Partner Tenax Therapeutics Misses Primary Endpoint in Phase 3 LEVEL Trial for PH-HFpEF

A Phase 3 failure for oral levosimendan in PH-HFpEF now places Orion Corporation and its license partner Tenax Therapeutics at a regulatory inflection point, with the registrational pathway requiring renegotiation before either agency or manufacturing commitments can be confirmed. Tenax announced on 10 August 2026 that the LEVEL trial did not meet its primary endpoint of improvement in 6-minute walk distance versus placebo, nor the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.

The clinical picture is not a clean null result. Prespecified subgroup analyses identified a substantial beneficial treatment effect in patients with greater disease burden, and clinically meaningful changes were observed in predefined cardiac biomarker and pulmonary hemodynamic measures across the overall trial population. Safety data remained broadly supportive: serious adverse events and adjudicated clinical worsening events were balanced across treatment arms, and the compound was generally well tolerated.

For regulatory affairs leads, the immediate operational read centres on Tenax's stated intention to request a Type C Meeting with the FDA to discuss revisions to the ongoing registrational development program, alongside parallel scientific consultation from the European Medicines Agency. That dual-agency engagement signals a strategy of preserving optionality across geographies rather than a full program withdrawal, but it also introduces timeline uncertainty that will propagate into CMC and manufacturing planning cycles.

Plant heads and supply chain functions supporting levosimendan's oral formulation development should treat the Type C Meeting request as a trigger for scenario planning. Depending on whether FDA accepts a refined patient population, revised endpoints, or an alternative trial design, process validation activities and batch manufacturing commitments tied to the original registrational timeline may require reassessment. Parallel EMA consultation adds a second regulatory clock, and divergence between agency positions on acceptable evidence packages is a realistic outcome that would further complicate manufacturing scale decisions.

Orion's exposure is indirect but material: levosimendan sits within a licensing arrangement, meaning that Tenax's regulatory pivot will determine whether Orion's technology transfer and supply obligations under that agreement accelerate, pause, or are restructured. The outcome of the Type C Meeting request, and the FDA's willingness to engage on a revised development framework, will set the next measurable checkpoint for both organisations.

Source: Orion Corporation via GlobeNewswire, 10 August 2026.